Demitria Hernandez, MD
Hospitalist · New York, NYNPI 1801034194
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $153, 4.5 times the $34 reported in 2023.
Across 11 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$40
- Kestra Medical Technology Services, Inc.$38
- Ceribell, Inc.$36
- Exact Sciences$35
- Abbott$34
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21
- plus $57 from 3 others
What the payments were for
- Food & beverage$262100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $38 |
| Ceribell, Inc. | 1 | $36 |
| Exact Sciences | 2 | $35 |
| Abbott | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Pfizer | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $17 |
How this compares
$262 in reported general payments places this provider in the 70th percentile of 1,860 hospitalist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 23 | $155 |
| ClopidogrelClopidogrel Bisulfate | 24 | $139 |
| Atorvastatin Calcium | 23 | $108 |
| Nitroglycerin | 11 | $107 |
| Metoprolol Tartrate | 23 | $60 |
| Amlodipine Besylate | 24 | $39 |
| Furosemide | 15 | $28 |
| Prednisone | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in New York
- Yair SapersteinNew York$43K
- Timothy TiutanNew York$42K
- Natasha VartakNew York$35K
- Sunil BhattNew York$25K
- Domenico AcciliNew York$21K
- Peter TingNew York$17K
- Amihai RottenstreichNew York$16K
- Matthew McCarthyNew York$12K
- John ChelicoNew York$11K
- Richard LinNew York$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.